The Food and Drug Administration (FDA) has approved a new weight loss drug called Zepbound from Eli Lilly. Zepbound is a GLP-1 agonist, which means it mimics hormones that help reduce food intake and appetite. In clinical trials, Zepbound was shown to be more effective than other weight loss medications on the market, leading to an average weight loss of 22.5% body weight, or about 52 pounds.
Zepbound is expected to be available in the U.S. by the end of the year and will carry a list price of about $1,060 for a month’s supply. The high cost of the drug may make it out of reach for many people, as insurance companies are often reluctant to cover weight loss medications and Medicare does not cover them.
Despite the high cost, some analysts have predicted that Zepbound could become the best-selling drug in history.
In addition to its weight loss benefits, Zepbound may also improve how the body breaks down sugar and fat. However, the drug also carries a risk of gastrointestinal issues, including nausea, diarrhea, vomiting, constipation, and stomach pain.
Overall, Zepbound is a promising new treatment for obesity, but it is important to consider the potential side effects and cost before starting the medication.
Here are some key points to remember from the article:
- Zepbound is a new weight loss drug that has been shown to be effective in clinical trials.
- Zepbound is a GLP-1 agonist, which means it mimics hormones that help reduce food intake and appetite.
- Zepbound is expected to be available in the U.S. by the end of the year and will carry a list price of about $1,060 for a month’s supply.
- Zepbound may also improve how the body breaks down sugar and fat.
- Zepbound carries a risk of gastrointestinal issues, including nausea, diarrhea, vomiting, constipation, and stomach pain.